Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, will present and host one-on-one meetings at Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston on Nov. 10, 2026. President and CEO Seth Lederman, M.D., will deliver the company presentation from 4 to 4:25 p.m. ET, with a live webcast and replay available under the News & Events tab in the Investors section of the company's website. The presentation matters because it offers investors a direct look at a company that has recently crossed a significant milestone: the approval of its flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years.
Tonix is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports marketed products including acute migraine therapies Zembrace SymTouch and Tosymra, while the company maximizes the science behind TONMYA in Phase 2 clinical trials evaluating its potential in major depressive disorder and acute stress disorder. The CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Beyond CNS, Tonix is advancing immunology programs such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs remain investigational; their efficacy and safety have not been established and they have not been approved for any indication.
The conference appearance is important because it allows Tonix to engage directly with healthcare investors and potential partners at a time when its commercial launch and pipeline progress are both in focus. For a company with a newly approved product and multiple clinical-stage assets, such visibility can help translate scientific progress into market recognition. The full press release is available at https://ibn.fm/f7udM, and ongoing news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
The announcement was distributed through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides services including editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For investors, the key implication is that Tonix's conference presentation could sharpen the market's understanding of how the company plans to build on its first commercial approval and advance a diversified pipeline across CNS and immunology.
